Sanofi SA (FRA:SNW)
€ 92.33 -1.89 (-2.01%) Market Cap: 115.85 Bil Enterprise Value: 125.29 Bil PE Ratio: 21.94 PB Ratio: 1.59 GF Score: 89/100

Sanofi SA to Discuss Phase 2b Results Of The Investigational BTK Inhibitor ('168) In Relapsing Multiple Sclerosis Conference Call Transcript

Apr 23, 2020 / 02:00PM GMT
Release Date Price: €88.32 (+0.19%)
Felix Lauscher
Sanofi - Head of IR North America & Asia

Good morning and good afternoon to everyone on the call. I hope everyone is safe and remaining healthy. Thank you for joining us to review the Phase II results of our brain-penetrant BTK inhibitor '168. As usual, you can find the slides to this call on the Investors page of our website at sanofi.com.

Moving to Slide 2. I would like to remind you that information presented in this call contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d'Enregistrement Universel for a description of these risk factors.

With that, please advance to Slide 3. Our speakers today in the order of presenting are Bill Sibold, Executive Vice President, Specialty Care; Erik Wallström, Therapeutic Area Head, Neurology Development; Rita Balice-Gordon, Therapeutic Area Head, Neurologic and Rare Disease Research; and John Reed, Executive Vice President, Global Head of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot